生物活性产品针对C-Met作为潜在的抗瘤药物
Liying Zhao1, Chunmei Qian1,2, Xiaoqi Ma1
1Experiment Center for Science and Technology, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
用新型抑制剂向介质细胞-上皮细胞转变因子 (c-Met) 显示出克服瘤中耐药性的前景. 研究正在从天然化合物和传统中医药中开发c-Met抑制剂方面取得进展.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 介酶-表皮转变因子 (c-Met),一个受体氨酸激酶 (RTK),对于细胞增殖,迁移,入侵和瘤转移至关重要.
- 瘤耐药性是一个越来越大的挑战,需要开发新的抗癌药物.
研究的目的:
- 审查c-Met抑制剂的发展,作为对抗耐药瘤的潜在治疗策略.
- 总结一下来自自然化合物和传统中国医学 (TCM) 的抗c-Met药物.
主要方法:
- 在科学数据库 (ScienceDirect,PubMed,Wiley,SSCI) 中进行全面的文献搜索.
- 对相关文献进行查和审查,重点关注c-Met通路和抗瘤作用.
- 使用雪球方法来确定额外的高质量研究.
主要成果:
- 在开发小分子向药物,包括c-Met抑制剂方面取得了重大进展.
- 从自然化合物和TCM中成功合成和分离c-Met抑制剂.
结论:
- 本次审查巩固了来自自然产品和TCM的抗c-Met药物的当前发展.
- 为未来开发用于癌症治疗的新型c-Met抑制剂提供基础资源.
更多相关视频
10:46A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
Published on: September 13, 2022
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Mitogens and the Cell Cycle
Inhibition of Cdk Activity
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
